Affilogic

Affilogic is leveraging the versatility of its proprietary Nanofitin® technology to design and develop targeted therapies in a variety of indications including CNS diseases. Nanofitins are small affinity proteins selective of chosen epitopes from targets of interest, acting as APIs or vectors. In particular, Affilogic has discovered Nanofitins against a series of BBB targets to promote receptor-mediated transcytosis. Several formats have been designed to transport APIs – proprietary or through co-development partnerships – such as full-length mAbs, enzymes and nucleic acids, into the brain.

www.affilogic.com